Faculty profile

Jean-Simon Diallo

Back to faculty

Assistant ProfessorBiochemistry, Microbiology and ImmunologyUniversity of Ottawa

Jean-Simon Diallo

Assistant Professor

Biochemistry, Microbiology and Immunology

Faculty of Medicine

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
30 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (6 CIHR, 1 SSHRC, 1 NSERC), most recently in 2026.
Supervised 3 trainees who won CIHR awards, most recently in 2020.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

968

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

University Profile Personal Website Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Ottawa profile.

Vaccines Small Molecule Oncolytic Virus Biodefence Biomanufacturing Doe Emergency Preparedness High-Throughput Screening

Latest papers

Lipidomic profiling of influenza A virus production in MDCK cells towards targeted clone selection.
Scientific reports · 2026
Optimization of YF17D-Vectored Zika Vaccine Production by Employing Small-Molecule Viral Sensitizers to Enhance Yields.
Vaccines · 2025
Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.
Nature biomedical engineering · 2025

All 77 publications

Latest funding

A Scalable, Small Molecule Enhanced High-Yield Suspension Vero Platform for VSV-Vectored Vaccine Yield to Strengthen Epidemic and Biodefence Preparedness
CIHR · 2026 · Nominated PI
$300,000
Improving and accelerating viral therapeutics biomanufacturing through lipidomics method
SSHRC · 2023 · Principal investigator
$249,573
Advanced Biomanufacturing Innovations
SSHRC · 2023 · Co-investigator
$5,770,277

All 18 grants and awards

77 publications.

Lipidomic profiling of influenza A virus production in MDCK cells towards targeted clone selection.

Menard JA, Zinnecker T, Godbout E, Roberts JA, Arulanandam R, Chen A, Landry A, Boddy CN, Reichl U, Diallo JS, Genzel Y, Smith JC

Scientific reports2026

DOI: 10.1038/s41598-025-33499-1 PMID: 41501381

Optimization of YF17D-Vectored Zika Vaccine Production by Employing Small-Molecule Viral Sensitizers to Enhance Yields.

Göbel S, Zinnecker T, Jordan I, Sandig V, Vervoort A, de Jong J, Diallo JS, Satzer P, Satzer M, Dallmeier K, Reichl U, Genzel Y

Vaccines2025

DOI: 10.3390/vaccines13070757 PMID: 40733734

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

Rezaei R, Boulton S, Ahmadi M, Petryk J, Da Silva M, Kooshki Zamani N, Singaravelu R, St-Laurent G, Daniel L, Sadeghipour A, Pelin A, Poutou J, Munoz Zuniga AI, Choy C, Gilchrist VH, Khalid Z, Austin B, Onsu KA, Marius R, Ameli Z, Mohammadi F, Mancinelli V, Wang E, Nik-Akhtar A, Alwithenani A, Panahi Arasi F, Ferguson SSG, Hobman TC, Alain T, Tai LH, Ilkow CS, Diallo JS, Bell JC, Azad T

Nature biomedical engineering2025

DOI: 10.1038/s41551-024-01259-7 PMID: 39609558

Activation and Evasion of the FEAR Pathway by RNA Viruses.

Rex EA, Seo D, Embry A, Arulanandam R, Spinelli MM, Diallo JS, Gammon DB

bioRxiv : the preprint server for biology2025

DOI: 10.1101/2024.08.22.609092 PMID: 40060670

Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer

Cudmore AO, Rodriguez GM, Maranda V, Boroujeni SF, Murshed H, Macdonald EA, Grondin M, Garson K, Matuszewska K, Diallo J-S

Molecular Cancer Therapeutics20251 citations

DOI: 10.1158/1535-7163.mct-24-0906

Comprehensive untargeted lipidomic profiling of third generation lentiviral vectors and packaging cells.

Roberts JA, Godbout E, Menard JA, Boddy CN, Diallo JS, Smith JC

Molecular omics2024

DOI: 10.1039/d4mo00052h PMID: 39378046

Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic AHF, Kress A, Carter-Timofte ME, Holm E, van der Horst D, Kollmann CF, Liu Z, Wang C, Hoang HD, Kovalenko E, Chrysopoulou M, Twayana KS, Ottosen RN, Svenningsen EB, Begnini F, Kiib AE, Kromm FEH, Weiss HJ, Di Carlo D, Muscolini M, Higgins M, van der Heijden M, Arulanandam R, Bardoul A, Tong T, Ozsvar A, Hou WH, Schack VR, Holm CK, Zheng Y, Ruzek M, Kalucka J, de la Vega L, Elgaher WAM, Korshoej AR, Lin R, Hiscott J, Poulsen TB, O'Neill LA, Roy DG, Rinschen MM, van Montfoort N, Diallo JS, Farin HF, Alain T, Olagnier D

Nature communications2024

DOI: 10.1038/s41467-024-55044-w PMID: 39702301

High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity.

Wong B, Birtch R, Bergeron A, Ng K, Maznyi G, Spinelli M, Chen A, Landry A, Crupi MJF, Arulanandam R, Ilkow CS, Diallo JS

Scientific reports2024Senior author

DOI: 10.1038/s41598-024-76855-3 PMID: 39550388

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.

Taha Z, Crupi MJF, Alluqmani N, MacKenzie D, Vallati S, Whelan JT, Fareez F, Alwithenani A, Petryk J, Chen A, Spinelli MM, Ng K, Sobh J, de Souza CT, Bharadwa PR, Lee TKH, Thomas DA, Huang BZ, Kassas O, Poutou J, Gilchrist VH, Boulton S, Thomson M, Marius R, Hooshyar M, McComb S, Arulanandam R, Ilkow CS, Bell JC, Diallo JS

Nature communications2024Senior author

DOI: 10.1038/s41467-024-51498-0 PMID: 39179564

A cyclic lipopeptide from Fusarium graminearum targets plant membranes to promote virulence.

Brauer EK, Bosnich W, Holy K, Thapa I, Krishnan S, Moatter Syed, Bredow M, Sproule A, Power M, Johnston A, Cloutier M, Haribabu N, Izhar U H Khan, Diallo JS, Monaghan J, Chabot D, Overy DP, Subramaniam R, Piñeros M, Blackwell B, Harris LJ

Cell reports2024

DOI: 10.1016/j.celrep.2024.114384 PMID: 38970790

A Scalable, Small Molecule Enhanced High-Yield Suspension Vero Platform for VSV-Vectored Vaccine Yield to Strengthen Epidemic and Biodefence Preparedness

Nominated PICIHR2026Operating Grant: Leadership Award for Vaccine Research - NRC-CIHR

Principal investigators: Diallo, Jean-Simon

Keywords: Ai; Biodefence; Biomanufacturing; Doe; Emergency Preparedness; High-Throughput Screening; Small Molecule; Vaccines; Vero; Vsv

$300,000

Improving and accelerating viral therapeutics biomanufacturing through lipidomics method

Principal investigatorSSHRC2023New Frontiers in Research Fund - Exploration

Principal investigators: Diallo, Jean-Simon

Keywords: Biomanufacturing; Lipidomics; Viral medicine; Lentivirus; Mass spectrometry; Lipids; Medicinal chemistry; Viral vector

$249,573

Advanced Biomanufacturing Innovations

Co-investigatorSSHRC2023Canada Biomedical Research Fund and Biosciences Research Infrastructure Fund

Principal investigators: Lajeunesse, Robert

Keywords: biomanufacturing; vaccines; cell lines; process development; quality programs

$5,770,277

COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals

Co-investigatorCIHR2021Operating Grant: SARS-CoV-2 variants supplement stream 1

Principal investigators: Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J

Keywords: Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine

$50,000

Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals

Co-investigatorCIHR2020Operating Grant: COVID-19 Rapid Research Funding Opportunity - Vaccines

Principal investigators: Bell, John C; Ilkow, Carolina S; Lapointe, Réjean; Mahoney, Douglas J

Keywords: Covid-19; Epitopes; Immunity; Infection; Manufacturing; Pre-Clinical; Sars-Cov-2; Vaccine

$1,936,150

Biotherapeutic implications for oncolytic virus-induced MHC class I ligandomes

Co-investigatorCIHR2020Project Grant

Principal investigators: Gujar, Shashi A

Keywords: Antitumor Immunity; Cancer; Cancer Immunotherapy; Mhc Class I; Oncolytic Virus

$1,063,350

Engineering and characterization of a novel immunomodulatory oncolytic virus via modification of cellular phosphorylation homeostasis

SupervisorCIHR2020Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Wong, Boaz

Keywords: Cancer Therapeutics; Combinational Therapy; Genetic Engineering; Immunity; Immunological Memory; Interferon; Oncolytic Virus; Therapeutic Development; Viral Sensitizers

$105,000

Novel oncolytic virus vaccines exploiting dendritic cell targeting

Nominated PICIHR2018Operating Grant: CCS Innovation Grants

Principal investigators: Diallo, Jean-Simon

Keywords: Novel Oncolytic Virus Vaccines

$100,000

Development of Viral Sensitizing Antibody Drug Conjugate and Oncolytic virus Combination Regimens for the Treatment of Breast Cancer

Nominated PICIHR2017Project Grant

Principal investigators: Diallo, Jean-Simon

Keywords: Antibody-Drug Conjugates; Her2; Immunotherapy; Medicinal Chemistry; Oncolytic Virotherapy; Targeted Therapies; Viral Sensitizers

$776,475

Viral sensitizer technology for increasing yield of vaccines produced in cell culture

Principal investigatorNSERC2016Collaborative Research and Development Grants

Principal investigators: Diallo, JeanSimon

$270,000

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Jean-Simon Diallo

Research

Latest papers

Latest funding

Lipidomic profiling of influenza A virus production in MDCK cells towards targeted clone selection.

Optimization of YF17D-Vectored Zika Vaccine Production by Employing Small-Molecule Viral Sensitizers to Enhance Yields.

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses.

Activation and Evasion of the FEAR Pathway by RNA Viruses.

Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer

Comprehensive untargeted lipidomic profiling of third generation lentiviral vectors and packaging cells.

Author Correction: Octyl itaconate enhances VSV&#x394;51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV&#x2206;51 activity.

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.

A cyclic lipopeptide from Fusarium graminearum targets plant membranes to promote virulence.

A Scalable, Small Molecule Enhanced High-Yield Suspension Vero Platform for VSV-Vectored Vaccine Yield to Strengthen Epidemic and Biodefence Preparedness

Improving and accelerating viral therapeutics biomanufacturing through lipidomics method

Advanced Biomanufacturing Innovations

COVID-19 Variant Supplement - Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals

Development of Vaccines to Prevent SARS-CoV-2 Infection of High Risk Individuals

Biotherapeutic implications for oncolytic virus-induced MHC class I ligandomes

Engineering and characterization of a novel immunomodulatory oncolytic virus via modification of cellular phosphorylation homeostasis

Novel oncolytic virus vaccines exploiting dendritic cell targeting

Development of Viral Sensitizing Antibody Drug Conjugate and Oncolytic virus Combination Regimens for the Treatment of Breast Cancer

Viral sensitizer technology for increasing yield of vaccines produced in cell culture

Frequent collaborators

Tommy Alain

Brian Lichty

Hesham Abdelbary

Rebecca Auer

Harold Atkins

Natasha Kekre

Joel Werier

Jovian Tsang

Jaahnavi Dave

Barbara Vanderhyden

Taha Azad

Nahum Sonenberg

Michele Ardolino

Rongtuan Lin

Yonghong Wan

John Bell

Shashi Gujar

Julien Van Grevenynghe

Michael Ong

Leonardo Susta

Abolfazl Nik-Akhtar

Bruce Burns

Bryan Lo

Karen Mossman

Eric Brown

J Michael Paterson

James Petrik

Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.

High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity.